R&D News | pharmaphorum

News

With $75m cash injection, SynOx plans ph3 rare tumour trial

Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into ph

News

Ipsen signs $1.8bn RNA drug alliance with Skyhawk

Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for ra

News

Hyundai Bio plans trials of antiviral for dengue fever

South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral

News

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, wh

News

Metsera lands with $290m to take on obesity giants

Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that start-up Metsera has launched with an impre

News

FDA fast-tracks AskBio’s heart failure gene therapy

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficac

With $75m cash injection, SynOx plans ph3 rare tumour trial

Ipsen signs $1.8bn RNA drug alliance with Skyhawk

Hyundai Bio plans trials of antiviral for dengue fever

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

Metsera lands with $290m to take on obesity giants

FDA fast-tracks AskBio’s heart failure gene therapy

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks